Pharmaceuticals Global On demand · 24-48h

Global Fibrinogen Market Strategic Research Report

Global Fibrinogen Market Strategic Research Report
$3,500 USD
Market Research Reports
Strategic Research Report
Global Fibrinogen Market
$1.44B2025
10.1%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Human Fibrinogen, Animal Fibrinogen

By Application: Congenital Fibrinogen Deficiency, Surgical Procedures, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: CSL Behring, LFB Group, Shanghai RAAS Blood Products, China Resources Boya Bio-pharmaceutical, Hualan Biological Engineering, Harbin Pacific Biopharmaceutical, China Meheco Group, Taibang Biologic, Octapharma

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 97 pages
Market size 2025
$1.44B
Billion USD
Forecast CAGR
10.1%
2025-2032
Forecast 2032
$2.8B
Projected
Regions
5
Asia Pacific · Latin America · MEA · Europe · North America

Overview

Scope of the Report

The global Fibrinogen market size is predicted to grow from US$ 1,443 million in 2025 to US$ 2,802 million in 2032; it is expected to grow at a CAGR of 10.1% from 2026 to 2032.

Fibrinogen (factor I) is a glycoprotein in vertebrates that helps in the formation of blood clots. Fibrinogen Concentrate is used as a medicine for blood disease. Fibrinogen concentrate is a preparation of coagulation factors prepared from pooled plasma. Currently, only RiaSTAP (CSL Behring) is licensed in a number of countries for multiple indications including treating acute bleeding episodes with Hypofibrinogenemia. Other manufacturer’s products are justly used in local region or countries.

The market for fibrinogen is primarily driven by the increasing prevalence of bleeding disorders and surgical procedures that require rapid hemostasis, as well as growing awareness and adoption of targeted blood management therapies. Advances in plasma fractionation and recombinant technologies, along with rising demand for safer, pathogen-reduced, and high-purity blood products, are also fueling market growth. Additionally, an aging population, higher incidence of trauma and cardiovascular surgeries, and expansion of healthcare infrastructure in emerging regions contribute to the increasing demand for fibrinogen concentrate.

Global core fibrinogen manufacturers include CSL Behring, LFB Group and Shanghai RAAS Blood Products etc. The top 1 companies hold a share about 52%. North America is the largest market, with a share about 31%, followed by Europe and Asia Pacific with the share about 28% and 26%.

This report presents a comprehensive overview of the global Fibrinogen market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Human Fibrinogen
  • Animal Fibrinogen

Segment by Application

  • Congenital Fibrinogen Deficiency
  • Surgical Procedures
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Fibrinogen market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Congenital Fibrinogen Deficiency, Surgical Procedures, Others evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Fibrinogen Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 10.1%
Regional growth momentum
Market share by segment
Key metrics
Base value
$1.44B
2025
Forecast
$2.8B
2032
CAGR
10.1%
2025–2032
Regions
5
global
Key companies
CSL BehringLFB GroupShanghai RAAS Blood ProductsChina Resources Boya Bio-pharmaceuticalHualan Biological EngineeringHarbin Pacific BiopharmaceuticalChina Meheco GroupTaibang Biologic
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Human FibrinogenAnimal Fibrinogen
By Application
Congenital Fibrinogen DeficiencySurgical ProceduresOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Human Fibrinogen
  • 3.1.3 Animal Fibrinogen
  • 3.1.4 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Congenital Fibrinogen Deficiency
  • 4.1.3 Surgical Procedures
  • 4.1.4 Others
  • 4.1.5 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 CSL Behring
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 LFB Group
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Shanghai RAAS Blood Products
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 China Resources Boya Bio-pharmaceutical
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Hualan Biological Engineering
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Harbin Pacific Biopharmaceutical
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 China Meheco Group
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Taibang Biologic
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Octapharma
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global Fibrinogen market?
The global Fibrinogen market is estimated at US$ 1.44 billion in 2025 (base year) and is projected to reach US$ 2.8 billion by 2032.
What is the forecast CAGR for the Fibrinogen market?
The market is expected to grow at a CAGR of 10.1% from 2026 to 2032, expanding from US$ 1.44 billion in 2025 to US$ 2.8 billion in 2032, roughly 1.9 times its base-year value.
What is Fibrinogen?
Fibrinogen (factor I) is a glycoprotein in vertebrates that helps in the formation of blood clots. Fibrinogen Concentrate is used as a medicine for blood disease. Fibrinogen concentrate is a preparation of coagulation factors prepared from pooled plasma.
What are the main segments of the Fibrinogen market by type?
By type, the market is segmented into Human Fibrinogen and Animal Fibrinogen.
Which applications drive demand in the Fibrinogen market?
Key applications covered include Congenital Fibrinogen Deficiency, Surgical Procedures and Others.
Who are the key players in the Fibrinogen market?
Key players profiled include CSL Behring, LFB Group, Shanghai RAAS Blood Products, China Resources Boya Bio-pharmaceutical, Hualan Biological Engineering, Harbin Pacific Biopharmaceutical, China Meheco Group and Taibang Biologic, among 9 companies covered in total.
Which regions and countries are covered for Fibrinogen?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What is driving growth in the Fibrinogen market?
The market for fibrinogen is primarily driven by the increasing prevalence of bleeding disorders and surgical procedures that require rapid hemostasis, as well as growing awareness and adoption of targeted blood management therapies.
Who should buy the Fibrinogen market report?
The report is intended for manufacturers and solution providers, distributors and end users in Congenital Fibrinogen Deficiency, Surgical Procedures and Others, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Fibrinogen market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from $3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.